Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

US12365689B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Mohamed-Eslam F. Mohamed · Gurnee, US
• Ahmed A. Othman · Libertyville, US
• Aileen L. Pangan · La Grange, US
• Ben Klünder · Ludwigshafen, DE
• Heidi S. Camp · Winnetka, US
• Robert J. Padley · Highland Park, US
• Jeffrey W. Voss · Hudson, US
• Cheng Thiam Tan · Grayslake, US

Key dates

• Filing date: Oct 11, 2024
• Grant date: Jul 22, 2025
• Expiry date: Oct 11, 2044

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to solid-state forms and corresponding pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, and methods of treatment, including treatment of rheumatoid arthritis and juvenile idiopathic arthritis using the same. The treatment methods generally comprise administering to a patient (e.g., a pediatric patient) a therapeutically effective amount of upadacitinib as a stable liquid pharmaceutical composition or a solid dosage form, at a dose based on patient body weight.